KNSA
Income statement / Annual
Last year (2024), Kiniksa Pharmaceuticals, Ltd.'s total revenue was $423.24 M,
an increase of 56.60% from the previous year.
In 2024, Kiniksa Pharmaceuticals, Ltd.'s net income was -$43.19 M.
See Kiniksa Pharmaceuticals, Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$423.24 M |
$270.26 M |
$220.18 M |
$38.54 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$60.91 M
|
$56.52 M
|
$22.90 M
|
$9.10 M
|
$3.81 M
|
$3.28 M
|
$286.00 K
|
$28.00 K
|
$22.00 K
|
| Gross Profit |
$362.33 M
|
$213.74 M
|
$197.29 M
|
$29.44 M
|
-$3.81 M
|
-$3.28 M
|
-$286.00 K
|
-$28.00 K
|
-$22.00 K
|
| Gross Profit Ratio |
0.86
|
0.79
|
0.9
|
0.76
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$111.62 M
|
$76.10 M
|
$65.49 M
|
$99.30 M
|
$109.64 M
|
$132.93 M
|
$86.60 M
|
$56.36 M
|
$17.44 M
|
| General & Administrative Expenses |
$156.58 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$21.56 M
|
$9.04 M
|
$6.56 M
|
| Selling & Marketing Expenses |
$11.43 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$168.01 M
|
$129.43 M
|
$97.95 M
|
$85.95 M
|
$43.92 M
|
$33.75 M
|
$21.56 M
|
$9.04 M
|
$6.56 M
|
| Other Expenses |
$128.31 M
|
$33.41 M
|
$24.07 M
|
$835.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$407.95 M
|
$238.93 M
|
$187.51 M
|
$186.08 M
|
$153.56 M
|
$166.68 M
|
$108.16 M
|
$65.40 M
|
$24.00 M
|
| Cost And Expenses |
$468.86 M
|
$295.46 M
|
$210.41 M
|
$195.18 M
|
$157.36 M
|
$169.96 M
|
$108.16 M
|
$65.40 M
|
$24.00 M
|
| Interest Income |
$9.46 M
|
$8.54 M
|
$1.25 M
|
$97.00 K
|
$1.13 M
|
$6.05 M
|
$4.72 M
|
$529.00 K
|
$65.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.70 M
|
$2.34 M
|
$2.40 M
|
$2.36 M
|
$3.81 M
|
$3.28 M
|
$286.00 K
|
$28.00 K
|
$22.00 K
|
| EBITDA |
-$43.92 M |
-$22.86 M |
$12.18 M |
-$154.28 M |
-$152.42 M |
-$160.64 M |
-$107.87 M |
-$65.37 M |
-$23.98 M |
| EBITDA Ratio |
-0.1
|
-0.08
|
0.06
|
-4
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.11
|
-0.09
|
0.04
|
-4.06
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$9.46 M
|
$8.54 M
|
$1.25 M
|
$97.00 K
|
$1.13 M
|
$6.05 M
|
$4.72 M
|
$529.00 K
|
$65.00 K
|
| Income Before Tax |
-$36.15 M
|
-$16.65 M
|
$11.03 M
|
-$156.54 M
|
-$156.23 M
|
-$163.91 M
|
-$103.44 M
|
-$64.87 M
|
-$23.94 M
|
| Income Before Tax Ratio |
-0.09
|
-0.06
|
0.05
|
-4.06
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$7.04 M
|
-$30.74 M
|
-$172.34 M
|
$1.39 M
|
$5.15 M
|
-$2.05 M
|
-$214.00 K
|
$2.00 K
|
$36.00 K
|
| Net Income |
-$43.19 M
|
$14.08 M
|
$183.36 M
|
-$157.92 M
|
-$161.38 M
|
-$161.87 M
|
-$103.23 M
|
-$64.87 M
|
-$23.97 M
|
| Net Income Ratio |
-0.1
|
0.05
|
0.83
|
-4.1
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.6 |
0.2 |
2.64 |
-2.3 |
-2.61 |
-2.99 |
-3.49 |
-2 |
-0.74 |
| EPS Diluted |
-0.6 |
0.2 |
2.6 |
-2.3 |
-2.61 |
-2.99 |
-3.49 |
-2 |
-0.74 |
| Weighted Average Shares Out |
$71.42 M
|
$70.06 M
|
$69.38 M
|
$68.58 M
|
$61.84 M
|
$54.05 M
|
$29.55 M
|
$32.47 M
|
$32.47 M
|
| Weighted Average Shares Out Diluted |
$71.42 M
|
$71.92 M
|
$70.42 M
|
$68.58 M
|
$61.84 M
|
$54.05 M
|
$29.55 M
|
$32.47 M
|
$32.47 M
|
| Link |
|
|
|
|
|
|
|
|
|
